Epizyme Initiates Pediatric MLL-r Proof-of-Concept Study for EPZ-5676

[PR Newswire] – CAMBRIDGE, Mass., May 7, 2014 /PRNewswire/ — Epizyme, Inc. (EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced the initiation of more

View todays social media effects on EPZM

View the latest stocks trending across Twitter. Click to view dashboard

See who Epizyme is hiring next, click here to view